Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Research ArticleOriginal Article

Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma

Fengjuan Jiang, Hui Liu, Fengping Peng, Zhaoyun Liu, Kai Ding, Jia Song, Lijuan Li, Jin Chen, Qing Shao, Siyang Yan, Kim De Veirman, Karin Vanderkerken and Rong Fu
Cancer Biology & Medicine August 2021, 18 (3) 721-733; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0430
Fengjuan Jiang
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui Liu
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fengping Peng
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhaoyun Liu
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai Ding
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jia Song
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lijuan Li
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin Chen
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qing Shao
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siyang Yan
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim De Veirman
2Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels 1090, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Vanderkerken
2Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels 1090, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rong Fu
1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rong Fu
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 18 no. 3 721-733
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2020.0430

Published By 
Cancer Biology & Medicine
History 
  • Received July 26, 2020
  • Accepted November 27, 2020
  • Published online August 1, 2021.

Copyright & Usage 
Copyright: © 2021, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

  1. Fengjuan Jiang1,*,
  2. Hui Liu1,*,
  3. Fengping Peng1,
  4. Zhaoyun Liu1,
  5. Kai Ding1,
  6. Jia Song1,
  7. Lijuan Li1,
  8. Jin Chen1,
  9. Qing Shao1,
  10. Siyang Yan1,
  11. Kim De Veirman2,
  12. Karin Vanderkerken2 and
  13. Rong Fu1⇑
  1. 1Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
  2. 2Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels 1090, Belgium
  1. Correspondence to: Rong Fu, E-mail: florai{at}sina.com
View Full Text
PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 18 (3)
Cancer Biology & Medicine
Vol. 18, Issue 3
1 Aug 2021
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma
Fengjuan Jiang, Hui Liu, Fengping Peng, Zhaoyun Liu, Kai Ding, Jia Song, Lijuan Li, Jin Chen, Qing Shao, Siyang Yan, Kim De Veirman, Karin Vanderkerken, Rong Fu
Cancer Biology & Medicine Aug 2021, 18 (3) 721-733; DOI: 10.20892/j.issn.2095-3941.2020.0430

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma
Fengjuan Jiang, Hui Liu, Fengping Peng, Zhaoyun Liu, Kai Ding, Jia Song, Lijuan Li, Jin Chen, Qing Shao, Siyang Yan, Kim De Veirman, Karin Vanderkerken, Rong Fu
Cancer Biology & Medicine Aug 2021, 18 (3) 721-733; DOI: 10.20892/j.issn.2095-3941.2020.0430
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Conclusions
    • Supporting Information
    • Grant support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • TNFSF15 facilitates the differentiation of CD11b+ myeloid cells into vascular pericytes in tumors
  • Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
  • Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial
Show more Original Article

Similar Articles

Keywords

  • Multiple myeloma
  • complement C3a
  • osteoclasts
  • PI3K/PDK1/SGK3 pathways
  • SGK inhibitor

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2023 Cancer Biology & Medicine

Powered by HighWire